UK

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

#GLP-1 #MHRA #Obesity #UK #Weight loss

Wegovy pill could help patients lose 17% body weight 

The new Wegovy pill could help patients lose 17% of their body weight, clinical trial results show.  The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available… Read More

#News

Pills
#MHRA #Obesity #UK #Weight loss

UK patients to benefit from approval of weight loss tablet  

UK patients will soon have access to a weight loss tablet following a landmark approval by the Medicines and Healthcare products Regulatory Agency (MHRA).  The body has approved oral Wegovy, which could be rolled out to as many as 100,000 patients living in the UK.  Research from healthcare company Simple… Read More

#News #Regulatory

#Cancer Research Horizons #CAR T-cell therapy #Drug discovery #Oncology #UK

On the Horizon – will In Vivo CAR-T fulfil its potential? 

DDW’s Maria Wallace attended Cancer Research Horizons’ On the Horizon breakfast event to learn more about the latest opportunities and challenges in cancer drug discovery and development.  Leading experts from academia, pharma, biotech and investment met in London, UK Thursday 11 June to discuss the potential of in vivo CAR-T therapies to transform the future of… Read More

#News

Multiple myeloma
#Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends quadruplet regimen for multiple myeloma 

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) as a combination therapy for untreated multiple myeloma.  NICE recommended the therapy, developed by Johnson & Johnson, with bortezomib, lenalidomide and dexamethasone (D-VRd) for untreated multiple myeloma in adults when an autologous stem cell transplant (ASCT) is unsuitable.  The recommendation is… Read More

#News #Regulatory

Scientist looking through microscope
#Cancer research #Clinical trial #Genetic profiling #The Royal Marsden NHS Foundation Trust #UK

UK cancer patients to benefit from genetic testing rollout 

Hundreds of UK cancer patients will benefit from a rollout of specialised blood tests, providing improved access to genetic testing and personalised therapies.  The Royal Marsden, who are partnering with Guardant Health, will provide circulating tumour DNA (ctDNA) molecular profiling, using the Guardant360 Liquid assay powered by Infinity.   These… Read More

#News

Laboratory research
#Advanced Therapies #Clinical trial #UK

UK introduces framework for advanced therapy trials 

The UK is set to introduce a national framework to boost advanced therapy clinical trials.  The Advanced Therapy Clinical Trials Capability Framework, produced jointly by the Advanced Therapy Treatment Centre (ATTC) network, the Cell and Gene Therapy Catapult and Skills for Health, provides a shared strategic resource… Read More

#News

#Cancer research #Medicines Discovery Catapult #Nuclear medicine #Radiopharmaceuticals #UK

Is the UK set to become a radiopharma leader?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Dr Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult. MDC recently announced a partnership with the UK National Nuclear Lab, and Maynard’s… Read More

#Cancer Research #Featured Podcasts #Podcasts

#Parkinson's #R&D #UK

UK centre opens to accelerate Parkinson’s treatment research 

A new UK research centre has opened to accelerate the search for treatments for Parkinson’s disease.   The £10 million ($13.5 million) UK Dementia Research Institute Parkinson’s Research Centre, jointly funded with Parkinson’s UK, will connect research teams at the University of Edinburgh, the University of Oxford and University College London. Read More

#News

#Biotech #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

How strong is the UK’s advanced therapy sector?  

DDW Editor Reece Armstrong speaks to Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult, about the UK’s strong position in advanced therapies and what the challenges are for making the country competitive within pharma.   RA: Why does the UK have a strong in position in clinical research for advanced therapies? … Read More

#Exclusive Content

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Stomach pain
#EnteroBiotix #Gastroenterology #Irritable Bowel Syndrome #UK

EnteroBiotix secures £19m to advance IBS treatment 

EnteroBiotix has announced it has secured £19 million ($26 million) in financing to advance a treatment for irritable bowel syndrome.  The biopharmaceutical company is set to use the investment to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic. EBX-102-02 will be advanced into Phase IIb development for… Read More

#Business & Investment #News

UK
#ABPI #AstraZeneca #Life sciences #UK

AstraZeneca investment strengthens UK’s position, CEO says 

AstraZeneca’s investment U-turn shows the UK is “a global destination for life sciences investment”, the ABPI’s Chief Executive has said.  Richard Torbett was speaking after AstraZeneca announced it would resume large-scale activity in the UK with a £300 million ($405 million) investment. The drugmaker had previously rolled back on investment in… Read More

#Business & Investment #News